Gastric Cancer

, Volume 21, Issue 6, pp 889–899 | Cite as

Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States

  • Brian De
  • Ryan Rhome
  • Vikram Jairam
  • Umut Özbek
  • Randall F. Holcombe
  • Michael Buckstein
  • Celina AngEmail author
Original Article



Evidence regarding gastric cancer patients < 40 years old is limited. This study examines young adults with gastric adenocarcinoma in the National Cancer Database to describe demographics and treatment practices, and to develop a nomogram to predict survival.


The database was queried for adult patients diagnosed with gastric adenocarcinoma from 2004 to 2013. Patients were stratified into two age groups: <40 and ≥ 40 years. The database was analyzed to compare demographics, clinical characteristics, and treatments used for each group. Differences in survival were assessed using Kaplan–Meier curves and log-rank test. For adults < 40 years old, an accelerated failure time survival model was fitted for overall survival and a descriptive nomogram was constructed.


Of 70,084 patients included, 2615 (4%) were < 40 years old and 67,469 (96%) were ≥ 40 years. Compared to older patients, adults < 40 years old were more likely to be female (46 vs. 35%), non-white (31 vs. 23%), Hispanic (32 vs. 11%), from the northeast (36 vs. 23%), and to present with stage IV disease (59 vs. 42%) and bone metastases (36 vs. 21%; p < 0.001 for all). The nomogram showed clinical stage as the strongest predictor of overall survival, followed by treatment, grade, race, Charlson–Deyo comorbidity score, and sex.


Young adults with gastric adenocarcinoma are more likely to be Hispanic, female, from the northeast, and to present with metastases. Despite these differences, clinical stage, treatment, and tumor grade are most predictive of overall survival for young adult patients.


Gastric Young NCDB Adenocarcinoma 



The authors wish to acknowledge the support of the Biostatistics Shared Resource Facility at Icahn School of Medicine at Mount Sinai and NCI Cancer Center Support Grant P30 CA196521-01. No other funding sources were used. The American College of Surgeon and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. For this type of study, formal consent is not required. This study was presented at the 2016 European Society of Medical Oncology Meeting in Copenhagen, Denmark.

Author contributions

Study concept and design: De and Ang. Administrative support: all authors. Provision of study materials: all authors. Collection and assembly of data: all authors. Data analysis and interpretation: all authors. Manuscript writing: De. Final approval of manuscript: all authors.

Compliance with ethical standards

Conflict of interest

Randall Holcombe reports personal fees from Anthem Healthcare and Merck, outside the submitted work, and also reports involvement in a colon cancer clinical trial as Chair of a Data Safety and Monitoring Committee, outside the submitted work. All other authors declare that they have no conflicts of interest.


  1. 1.
    Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson AB, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK (2017) Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. JNCI J Natl Cancer Inst. Scholar
  2. 2.
    Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Eheman CR, Ward EM (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120(9):1290–1314. Scholar
  3. 3.
    SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda.
  4. 4.
    Al-Refaie WB, Hu CY, Pisters PW, Chang GJ. Gastric adenocarcinoma in young patients: a population-based appraisal. Ann Surg Oncol. 2011;18(10):2800–7. Scholar
  5. 5.
    Smith BR, Stabile BE. (2009) Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg (Chicago, Ill: 1960) 144 (6):506–10. Scholar
  6. 6.
    Koea JB, Karpeh MS, Brennan MF. Gastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patients. Ann Surg Oncol. 2000;7(5):346–51.CrossRefGoogle Scholar
  7. 7.
    Kim KH, Kim YM, Kim MC, Jung GJ. Analysis of prognostic factors and outcomes of gastric cancer in younger patients: a case control study using propensity score methods. World J Gastroenterol. 2014;20(12):3369–75. Scholar
  8. 8.
    Kandel BP, Singh YP, Ghimire B. Unique features of gastric cancer in young patients: experience from a general hospital in Nepal. Asian Pac J Cancer Prevent: APJCP. 2016;17(5):2695–7.Google Scholar
  9. 9.
    Rona KA, Schwameis K, Zehetner J, Samakar K, Green K, Samaan J, Sandhu K, Bildzukewicz N, Katkhouda N, Lipham JC. Gastric cancer in the young: an advanced disease with poor prognostic features. J Surg Oncol. 2017;115(4):371–5. Scholar
  10. 10.
    Hsieh FJ, Wang YC, Hsu JT, Liu KH, Yeh CN. Clinicopathological features and prognostic factors of gastric cancer patients aged 40 years or younger. J Surg Oncol. 2012;105(3):304–9. Scholar
  11. 11.
    Zhou F, Shi J, Fang C, Zou X, Huang Q. Gastric carcinomas in young (younger than 40 years) Chinese patients: clinicopathology, family history, and postresection survival. Medicine. 2016;95(9):e2873. Scholar
  12. 12.
    Lopez-Basave HN, Morales-Vasquez F, Ruiz-Molina JM, Namendys-Silva SA, Vela-Sarmiento I, Ruan JM, Rosciano AE, Calderillo-Ruiz G, Diaz-Romero C, Herrera-Gomez A, Meneses-Garcia AA. Gastric cancer in young people under 30 years of age: worse prognosis, or delay in diagnosis? Cancer Manag Res. 2013;5:31–6. Scholar
  13. 13.
    Pisanu A, Podda M, Cois A, Uccheddu A. Gastric cancer in the young: is it a different clinical entity? A retrospective cohort study. Gastroenterol Res Pract. 2014;2014:125038. Scholar
  14. 14.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. Scholar
  15. 15.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30. Scholar
  16. 16.
    Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6. Scholar
  17. 17.
    Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96. Scholar
  18. 18.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. Scholar
  19. 19.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. Scholar
  20. 20.
    Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76. Scholar
  21. 21.
    Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. Scholar
  22. 22.
    Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717–26. Scholar
  23. 23.
    Geiger AM, Castellino SM. Delineating the age ranges used to define adolescents and young adults. J Clin Oncol. 2011;29(16):e492-e493. Scholar
  24. 24.
    Smith AW, Bellizzi KM, Keegan THM, Zebrack B, Chen VW, Neale AV, Hamilton AS, Shnorhavorian M, Lynch CF. Health-related quality of life of adolescent and young adult patients with cancer in the united states: the adolescent and young adult health outcomes and patient experience study. J Clin Oncol. 2013;31(17):2136–45. Scholar
  25. 25.
    Adolescent, Group YAOPR.. (2006) Closing the gap: research and care imperatives for adolescents and young adults with cancer (NIH Publication No. 06-6067). Department of Health and Human Services, National Institutes of Health, National Cancer Institute, and the LIVESTRONG Young Adult Alliance Bethesda, MDGoogle Scholar
  26. 26.
    Kikuchi S, Wada O, Nakajima T, Nishi T, Kobayashi O, Konishi T, Inaba Y (1995) Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Cancer 75 (12):2789–2793.<2789::AID-CNCR2820751202>3.0.CO;2-4CrossRefGoogle Scholar
  27. 27.
    Katai H, Sasako M, Sano T, Maruyama K. Gastric carcinoma in young adults. Jpn J Clin Oncol. 1996;26(3):139–43.CrossRefGoogle Scholar
  28. 28.
    Keegan THM, Ries LAG, Barr RD, Geiger AM, Dahlke DV, Pollock BH, Bleyer WA, For the National Cancer Institute Next Steps for A, Young Adult Oncology Epidemiology Working G. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer. 2016;122(7):1009–16. Scholar
  29. 29.
    Parsons HM, Harlan LC, Lynch CF, Hamilton AS, Wu X-C, Kato I, Schwartz SM, Smith AW, Keel G, Keegan THM. Impact of cancer on work and education among adolescent and young adult cancer survivors. J Clin Oncol. 2012;30(19):2393–400. Scholar
  30. 30.
    Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol. 2013;20(6):1759–65. Scholar
  31. 31.
    Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung cancer in the very young: treatment and survival in the national cancer data base. J Thorac Oncol. 2016;11(7):1121–31. Scholar
  32. 32.
    Stokes W, Amini A, Maroni PD, Kessler ER, Stokes C, Cost CR, Greffe BS, Garrington TP, Liu AK, Cost NG. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: a National Cancer Database analysis. J Pediatric Urol. 2017. Scholar
  33. 33.
    Pesce CE, Liederbach E, Czechura T, Winchester DJ, Yao K. Changing Surgical Trends in Young Patients with Early Stage Breast Cancer, 2003 to 2010: A Report from the National Cancer Data Base. J Am Coll Surg. 2014;219(1):19–28. Scholar
  34. 34.
    Chung HW, Noh SH, Lim JB. Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea. World J Gastroenterol. 2010;16(2):256–63.CrossRefGoogle Scholar
  35. 35.
    Isobe T, Hashimoto K, Kizaki J, Miyagi M, Aoyagi K, Koufuji K, Shirouzu K. Characteristics and prognosis of gastric cancer in young patients. Oncology reports. 2013;30(1):43–9. Scholar
  36. 36.
    Kojima O, Takahashi T, Kawakami S, Uehara Y, Matsui M. Localization of estrogen receptors in gastric cancer using immunohistochemical staining of monoclonal antibody. Cancer. 1991;67(9):2401–6.CrossRefGoogle Scholar
  37. 37.
    Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol. 2008;39(12):1809–15. Scholar
  38. 38.
    He Y, Luo H, Wang W, Chen J, Yao Y, Cai S, He J, Yan Y, Wu S, Hu X, Ke L, Niu J, Li H, Ji C, Hu B. Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis. Oncol Lett. 2015;9(6):2706–12. Scholar
  39. 39.
    Tamura PY, Curtiss C. Carcinoma of the stomach in the young adult. Cancer. 1960;13:379–85.CrossRefGoogle Scholar
  40. 40.
    Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw: JNCCN. 2016;14(10):1286–312.CrossRefGoogle Scholar
  41. 41.
    Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953–8. Scholar
  42. 42.
    Choi YY, Noh SH, Cheong JH. Evolution of gastric cancer treatment: from the golden age of surgery to an era of precision medicine. Yonsei Med J. 2015;56(5):1177–85. Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  • Brian De
    • 1
  • Ryan Rhome
    • 1
  • Vikram Jairam
    • 2
  • Umut Özbek
    • 3
  • Randall F. Holcombe
    • 4
  • Michael Buckstein
    • 1
  • Celina Ang
    • 5
    • 6
    Email author
  1. 1.Department of Radiation OncologyIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Department of Therapeutic RadiologyYale University School of MedicineNew HavenUSA
  3. 3.Department of Population Health Science and PolicyIcahn School of Medicine at Mount SinaiNew YorkUSA
  4. 4.University of Hawaii Cancer CenterUniversity of Hawaii at ManoaHonoluluUSA
  5. 5.Division of Hematology and Medical OncologyIcahn School of Medicine at Mount SinaiNew YorkUSA
  6. 6.Department of Medicine, Hematology and Medical OncologyMount Sinai HospitalNew YorkUSA

Personalised recommendations